Annual Report

Overview

The report describes Immutep's FY2024 progress from late-stage oncology trials, including the MSD collaboration for the Phase III TACTI-004 trial. It highlights successful scale-up of efti manufacturing to commercial 2,000L levels and a $100.2 million equity raise that extended the cash runway to calendar year 2026. It also introduces the company's ESG reporting initiative, while noting that the ESG Report is available separately on its website.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: Ends 30 June 2024
Publication date: 30 August 2024
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services